GlassScriptPhysician profile
Malinda D Folkert
NPI 1053048645
$1,012.98
in general payments reported to CMS, 2019-2025
21 companies · $746 in 2025
The $746 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.05 · 2023: $106 · 2024: $109 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $123.02 | 2025 | |
| Alexion Pharmaceuticals, INC. | $117.17 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $90.05 | 2025 | Hyqvia |
| Si-Bone, INC. | $89.41 | 2022-2023 | |
| Sk Life Science, INC. | $70.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $52.44 | 2025 | Rexulti |
| Neurelis, INC. | $47.49 | 2024-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $42.98 | 2025 | Wainua |
| Pfizer INC. | $42.78 | 2025 | |
| Kyowa Kirin, INC. | $42.25 | 2024 | Nourianz |
| Depuy Synthes Sales INC. | $39.14 | 2023 | Matrixneuro, Synthecel |
| Argenx US, INC. | $35.98 | 2025 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $34.41 | 2025 | |
| Silk Road Medical, INC. | $32.43 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Neurocrine Biosciences, INC. | $28.99 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $26.40 | 2025 | |
| Ucb, INC. | $24.86 | 2025 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $24.46 | 2025 | Austedo Xr |
| Genentech USA, INC. | $21.91 | 2025 | Ocrevus Zunovo |
| Tg Therapeutics, INC. | $13.47 | 2025 | |
| Arteriocyte Medical Systems, INC. | $13.34 | 2023 | Magellan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malinda Folkert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.